Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Yes DNDN hit $5.5b after approval for a mere four month survival extension but remember it was the first immunotherapy approved so there was a lot of excitement whereas the field is much more crowded now. If Lombardo is able to get our valuation up and sell the comonay for $50/up toward $2b, it will have been well worth the painful and long wait we have experienced.